Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2011

View Archived Issues

Genosco and Oscotec disclose promising therapeutics for acute myeloid leukemia

New serine/threonine-protein kinase Chk1 inhibitor shows antitumor in vivo

Two new allosteric nicotinic acetylcholine alpha4beta2 receptor modulators described

Merz Pharmaceuticals NME shows antidyskinetic efficacy

XenoPort reports on combination therapies for Parkinson's disease

Phase III trial in autism meets endpoints

Novel histamine H3 receptor ligands patented by Sanofi

Janssen Biotech and Pharmacyclics enter agreement for anticancer drug

Amgen describes new ALK tyrosine kinase receptor inhibitors

Acacia Pharma discloses phase IIa data on APD-209

CeNeRx BioPharma to advance TriRima trial

Novel lysophospholipid S1P1 receptor modulators characterized at Allergan

NanoViricides requests pre-IND meeting with FDA for anti-influenza candidate

Merck & Co. discovers new PRCP inhibitors

Metabolex announces results from arhalofenate/febuxostat combination study

Boehringer Ingelheim provides update on BI-201335 program

Nissan Chemical presents novel adiponectin receptor protein 1 agonists

FDA approves new oxybutynin gel product

OZ-439 reduces parasitemia in proof-of-concept study

Unigene Laboratories regains worldwide rights to oral PTH program

Vertex and Alios BioPharma begin trials of hepatitis C drug candidates

New topline data released from elvitegravir trial

Neoprobe to change name

Gedeon Richter gains extended marketing rights for Esmya

Takeda Pharmaceutical to launch new global vaccine business

ENGAGE-501 study evaluates entinostat in Hodgkin's lymphoma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...